Ianalumab targets the BAFF receptor, depleting malignant B cells and enhancing ibrutinib's efficacy, offering a potential ...

Targeted therapies, including BTK inhibitors and venetoclax, have replaced chemoimmunotherapy as the first-line standard for CLL, emphasizing patient preference and risk factors in treatment decisions ...

In " Beyond Diagnosis: CLL," Cleveland Clinic hematologist/oncologist Allison Winter, MD, and host John Mangels explore how ...

Embracing the natural rhythm of one's body, akin to Ikebana's irregular beauty, can lead to acceptance and resilience. A ...

The Indian Patent Office has rejected AbbVie's patent application for its cancer drug Venetoclax, citing a lack of inventive ...

Researchers analyzed the health records of more than 33,800 U.S. veterans diagnosed with non-melanoma skin cancer and found ...

The Indian Patent Office rejected AbbVie’s patent application for cancer drug Venetoclax (Venclexta), a decision expected to ease the entry of lower-cost generics.

GSK gets an entry in the list with Exdensur (depemokimab), a twice-yearly injectable IL-5 inhibitor for severe asthma, which ...

Oncoscope launches the first Real-time, AI-supported Living Systematic Literature Review designed for enterprise-wide ...

Ontario is the first province to fund Tagrisso for patients with non-small cell lung cancer, and Calquence for patients with previously untreated mantle ...

Detailed price information for Nurix Therapeutics Inc (NRIX-Q) from The Globe and Mail including charting and trades.